In Brief: Cambridge Biotech
Cambridge Biotech: Appoints Alison Taunton-Rigby, PhD, to president and CEO, the company announces April 7. Taunton-Rigby was most recently CEO of privately-held Cambridge Mass. biotech company Mitotix, which she left in December, and previously served as senior VP of Genzyme and as head of the Massachusetts Biotechnology Council. Cambridge Biotech also names interim CEO Jeffrey Deaver to chairman of the board replacing John Scott who remains as director and chairman emeritus...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth